Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter H Jones

Showing results (51-60 of 101) with videos related to

Pageof 11
Sort By:
Journal of Obesity|January 24, 2014
The impact of rapid weight loss on oxidative stress markers and the expression of the metabolic syndrome in obese individualsEva Tumova, Wensheng Sun, Peter H Jones, et al.
Journal of Clinical Lipidology|December 10, 2013
Modest diet-induced weight loss reduces macrophage cholesterol efflux to plasma of patients with metabolic syndromeMadhuri Vasudevan, Urbain Tchoua, Baiba K Gillard, et al.
The American Journal of Cardiology|February 2, 2008
Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levelsMasumi Ai, Seiko Otokozawa, Bela F Asztalos, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|May 13, 2006
Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemiaNicole E Jelesoff, Christie M Ballantyne, Antonios M Xydakis, et al.
The American Journal of Cardiology|October 13, 2016
Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized TrialsPeter H Jones, Harold E Bays, Umesh Chaudhari, et al.
The American Journal of Cardiology|September 18, 2004
Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemiaAntonios M Xydakis, John R Guyton, Philip Chiou, et al.
The American Journal of Cardiology|January 27, 2005
Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndromePrakash C Deedwania, Donald B Hunninghake, Harold E Bays, et al.
Clinical Cardiology|October 2, 2014
Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS StudiesJennifer G Robinson, Helen M Colhoun, Harold E Bays, et al.
Current Medical Research and Opinion|December 23, 2003
Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trialJames M McKenney, Peter H Jones, M Angeli Adamczyk, et al.
Journal of Clinical Lipidology|February 5, 2011
Efficacy and tolerability of multidrug therapy for hypertriglyceridemiaVenkateshwar R Polsani, Vijay Nambi, Salim S Virani, et al.
Pageof 11

Showing results (51-60 of 101) with videos related to

Sort By:
Pageof 11
Journal of Obesity|January 24, 2014
The impact of rapid weight loss on oxidative stress markers and the expression of the metabolic syndrome in obese individualsEva Tumova, Wensheng Sun, Peter H Jones, et al.
Journal of Clinical Lipidology|December 10, 2013
Modest diet-induced weight loss reduces macrophage cholesterol efflux to plasma of patients with metabolic syndromeMadhuri Vasudevan, Urbain Tchoua, Baiba K Gillard, et al.
The American Journal of Cardiology|February 2, 2008
Effects of maximal doses of atorvastatin versus rosuvastatin on small dense low-density lipoprotein cholesterol levelsMasumi Ai, Seiko Otokozawa, Bela F Asztalos, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|May 13, 2006
Effectiveness and tolerability of adding ezetimibe to niacin-based regimens for treatment of primary hyperlipidemiaNicole E Jelesoff, Christie M Ballantyne, Antonios M Xydakis, et al.
The American Journal of Cardiology|October 13, 2016
Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized TrialsPeter H Jones, Harold E Bays, Umesh Chaudhari, et al.
The American Journal of Cardiology|September 18, 2004
Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemiaAntonios M Xydakis, John R Guyton, Philip Chiou, et al.
The American Journal of Cardiology|January 27, 2005
Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidemia in patients with characteristics of the metabolic syndromePrakash C Deedwania, Donald B Hunninghake, Harold E Bays, et al.
Clinical Cardiology|October 2, 2014
Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS StudiesJennifer G Robinson, Helen M Colhoun, Harold E Bays, et al.
Current Medical Research and Opinion|December 23, 2003
Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trialJames M McKenney, Peter H Jones, M Angeli Adamczyk, et al.
Journal of Clinical Lipidology|February 5, 2011
Efficacy and tolerability of multidrug therapy for hypertriglyceridemiaVenkateshwar R Polsani, Vijay Nambi, Salim S Virani, et al.
Pageof 11